A Phase 1/2 interventional study of TA-8995 and Placebo in Elevated Lp(a), sponsored by Xention Ltd. Completed at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-16.
Sponsored by Xention Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study in males and females with elevated Lp(a) to look at the effects of TA-8995 on Lp(a) levels.
Xention Ltd is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10mg TA-8995 once daily
Drug: TA-8995
2.5mg TA-8995 once daily
Drug: TA-8995
Placebo to TA-8995 once daily.
Drug: Placebo
To evaluate the change from baseline in (Lp(a) levels after 12 weeks of treatment with TA-8995.
Time frame: 12 weeks
Number of participants with adverse events
Time frame: 12 weeks
The record gives a start of Sep 2014, a primary completion of Jan 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TA-8995
Xention Ltd